Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of Exicorilant in Healthy Subjects
NCT03335956Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Sep 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of exicorilant in castration-resistant prostate cancer (CRPC) (6 cohorts), sponsored by Corcept Therapeutics. Primary endpoint: Adverse Events (AEs). Started Sep 2017; status: completed.
02
Drugs
exicorilant
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT03335956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03335956.